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Mast cell activation is central to the pathophys-
iology of allergic asthma and other IgE-medi-
ated diseases and has more recently been shown 
to regulate both innate and adaptive immune 
responses (1, 2). Cross-linking of IgE receptors 
by antigen triggers signaling through the high 
affi   nity receptor for IgE (FcεRI) on mast cells 
and results in mast cell degranulation, lipid me-
diator production, and cytokine synthesis. Sev-
eral other biological mediators can infl  uence 
the magnitude of mast cell activation through 
this classical stimulatory pathway.
Adenosine is a ubiquitous mediator that 
has long been recognized to infl  uence mast 
cell function through activation of adeno-
sine receptors on the cell surface (3). Mast cells 
express the A2a, A2b, and A3 adenosine recep-
tors, and based on their diff  erential G protein 
coupling, it has been widely assumed that stim-
ulation of each receptor could infl  uence mast 
cell function in diff  erent ways (4–7). Of all of 
the adenosine receptors discovered to date, the 
biological functions of A2b have been the most 
diffi   cult to discern by pharmacological meth-
ods alone because of the diffi   culty in synthesiz-
ing agonists selective for this receptor subtype, 
as well as its capacity to couple to more than 
one G protein under conditions of forced ex-
pression and in some poorly diff  erentiated mast 
cell lines (4, 8–11). As a result, investigators 
have relied on combinatorial pharmacological 
approaches with nonselective A2b agonists and 
more selective receptor antagonists to ascribe 
function to this adenosine receptor subtype 
(4, 10, 12–14).
Using this approach, a proinfl  ammatory 
role for A2b on mast cells has been suggested 
by studies with the human leukemia mast cell 
line (HMC-1) and canine mastocytoma mast 
cell lines (BR cell lines) (4, 10, 13). In HMC-1 
cells, although neither A2a nor A3 selective ago-
nists increased proinfl  ammatory cytokine release, 
the nonselective adenosine receptor agonist 
adenosine-5′-N-ethylcarboxamide (NECA) in-
creased IL-8 release, and this eff  ect was blocked 
by the A2b-selective antagonist enprofylline. 
In the BR cell line, NECA, but not an A3-
selective agonist, could induce degranulation. 
This eff  ect of NECA could be blocked by the 
A2b-selective antagonist enprofylline. Although 
these studies suggest that A2b receptors can 
mediate the proinfl  ammatory eff  ects of aden-
osine on HMC-1 cells, it remains unknown 
whether these fi  ndings are relevant and opera-
tive in the intact organism and how adenosine 
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via A2b may infl  uence antigen-induced mast cell activation, 
because these poorly diff  erentiated cell lines do not express 
functional FcεRI receptors (15–17).
To determine the biological role of A2b on mast cells, we 
generated mice lacking the A2b adenosine receptor and have 
examined its contribution to antigen-induced mast cell acti-
vation in vitro and to antigen-induced anaphylaxis in vivo. 
Our data show that the A2b adenosine receptor functions 
as a negative regulator of mast cell activation by infl  uencing 
cyclic nucleotide homeostasis and intracellular calcium infl  ux 
into the mast cell.
RESULTS
Generation and characterization of A2b−/− mice
Mice carrying a mutant A2b allele were generated from 129/
SvEv embryonic stem (ES) cells in which homologous 
  recombination was used to replace part of the intron and the 
entirety of exon 2 (amino acids 113–332) with a marker gene 
(Fig. 1 A). Chimeric off  spring carrying the mutant A2b locus 
were identifi  ed by Southern blot analysis of tail biopsies and 
bred with C57BL/6 females (Fig. 1 B). After six consecutive 
crosses to C57BL/6, mice heterozygous for the mutation 
were intercrossed to generate homozygous congenic N6 
A2b−/− mice and A2b+/+ littermate controls. Examination 
of mRNA prepared from the brain and kidney of the A2b−/− 
mice showed the absence of the normal A2b transcripts pres-
ent in RNA preparations from A2b+/+ animals (Fig. 1 C). 
We also analyzed the transcriptional production of the A2b 
gene in A2b−/− bone marrow–derived mast cells (BMMCs) 
by quantitative RT-PCR. As shown in Fig. 1 D, A2b ex-
pression was undetectable in cells from A2b−/− animals. In 
contrast, A2b was abundantly expressed in BMMCs from 
A2b+/+ mice.
A2b−/− mice were born at expected Mendelian frequen-
cies, appeared healthy, and were grossly indistinguishable 
from A2b+/+ littermates. They achieve normal body weights 
and survive >1 yr. Both male and female A2b−/− mice have 
normal fertility. Histological analysis of all major organs 
  revealed no anatomical developmental abnormalities as a result 
of A2b inactivation. Specifi  c to this investigation, the num-
ber and morphology of mast cells in all tissues examined did 
not diff  er from that of A2b+/+ littermate controls (Table I). 
Evaluation of conscious, unchallenged mice by tail cuff   re-
vealed that blood pressure and pulse were similar between 
A2b−/− mice and A2b+/+ controls (systolic pressure: A2b−/− = 
116.3 ± 2.5 mmHg and A2b+/+ = 117.9 ± 3.7 mmHg 
[P = 0.72]; pulse: A2b−/− = 620.3 ± 10 bpm and A2b+/+ = 
639.8 ± 9.8 bpm [P = 0.2]), which suggests that, unlike the 
A2a receptor, the A2b receptor does not contribute to nor-
mal blood pressure homeostasis (18).
Enhanced anaphylaxis in A2b−/− mice
To evaluate the role of the A2b receptor on mast cells, pas-
sive anaphylaxis was examined by two models. In these mast 
cell–dependent models, exogenously administered IgE is pas-
sively taken up by mast cells, and degranulation is evoked by 
the subsequent administration of antigen. Passive systemic ana-
phylaxis (PSA) was elicited by intravenous injection of 20 μg 
anti-dinitrophenyl (DNP) IgE. After 24 h, mice received 
DNP–human serum albumin (DNP-HSA) antigen by intra-
venous injection. Core body temperature was recorded as a 
Figure 1.  Targeted disruption of the mouse A2b gene. (A) The tar-
geted disruption strategy consists of a targeting plasmid and genomic 
organization of the endogenous locus and targeted locus. The targeting 
plasmid is designed to disrupt the A2b gene by homologous recombination. 
The closed box represents exon 2 of the A2b gene, and the phosphoglycer-
ate kinase–thymidine kinase (PGK-TK) and PGK-Neo selection cassettes 
are indicated by empty boxes. Restriction sites are abbreviated as follows: 
X, Xba I; B, BamH I; and P, Psi I. The location of the 3′ external probe used 
to detect homologous recombination events for the Southern blot analysis 
is indicated. (B) Southern blot analysis of BamH I–digested mouse genomic 
DNA from tail biopsies. Blots were hybridized with the radiolabeled 1-kb 
probe outside of the targeted region of the A2b gene, resulting in an 8.3-kb 
band for the endogenous locus and a band shift to 6.2 kb for the targeted 
locus. (C) Northern blot analysis of A2b mRNA in A2b−/− and A2b+/+ mice. 
Total RNA extracts from the brain and kidney of A2b−/− and A2b+/+ mice 
were isolated and hybridized with a [32P]UTP-labeled cDNA probe (top) and 
β-actin probe (bottom) as loading controls. The arrows on the left indicate 
the two transcripts from the A2b+/+ mice, and the arrow on the right 
shows the presence of the truncated transcript in the targeted locus. 20 μg 
of total RNA was loaded for each lane. (D) Quantitative RT-PCR analysis of 
mRNA level of adenosine receptors in A2b+/+ versus A2b−/− BMMCs. Data 
are expressed as the mean transcript level ± SEM from three sets of 
A2b−/− and three sets of A2b+/+ cells. ND, no transcripts detected.JEM VOL. 204, January 22, 2007  119
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monitor of the magnitude of the systemic anaphylactic 
  response. As shown in Fig. 2 A, a greater temperature drop was 
observed in A2b−/− than in A2b+/+ animals (4.6 ± 0.24 vs. 
3.7 ± 0.29°C 10 min after DNP-HSA injection [P = 0.03]; 
6.9 ± 0.36 vs. 5.6 ± 0.28°C 20 min after DNP-HSA injec-
tion [P = 0.007]). Surprisingly,  30% of A2b−/− mice died 
after antigen challenge, whereas all A2b+/+ animals survived, 
as expected, throughout the duration of the experiment (P = 
0.049). As a result of this unexpected increase in the severity 
of the anaphylactic response with standard doses of IgE, all 
subsequent PSA experiments with A2b−/− mice were per-
formed with lower amounts of IgE loading. As shown in Fig. 
2 B, a more severe anaphylactic response was also observed in 
A2b−/− animals with a 10-fold lower dose (2 μg) of anti-
DNP IgE (P = 0.034).
To further establish whether the A2b receptor might play 
an important in vivo role in the regulation of mast cell func-
tion, mice were evaluated in a second model of IgE/mast 
cell–dependent anaphylaxis, passive cutaneous anaphylaxis 
(PCA). PCA was elicited by subcutaneous injection of anti-
DNP IgE into the pinna of the right ear. As an internal con-
trol, left ears were injected with the identical volume of 
vehicle. After 24 h, mice received antigen together with 
  Evans blue dye by intravenous injection. Mast cell–induced 
plasma protein exudation can be quantitated in this model by 
determining the levels of dye in tissue biopsies from IgE-
treated ears compared with those treated with vehicle. As 
shown in Fig. 3, Evans blue levels in biopsies from vehicle-
treated pinnae was no diff  erent between A2b−/− and A2b+/+ 
mice, suggesting that disruption of the A2b receptor did not 
modify basal vasopermeability. In contrast, extravasation in 
the IgE-treated pinnae was signifi   cantly higher than that 
present in vehicle-treated tissue in both A2b−/− and A2b+/+ 
mice, refl  ecting degranulation of mast cells by cross-linking 
of the FcεRI-bound anti-DNP IgE by antigen. Signifi  cantly 
greater plasma extravasation was observed in pinnae from 
A2b−/− animals loaded with 1 ng IgE (P = 7.36 × 10−6), 
suggesting enhanced antigen-induced mast cell degranuala-
tion in these genetically modifi  ed animals. However, when 
the IgE dose was increased to 100 ng, plasma protein extrava-
sation into the pinnae of A2b+/+ mice approached that seen 
in A2b−/− animals (P = 0.33).
To establish that our in vivo fi  ndings were the result of 
A2b defi  ciency on mast cells, mast cell–defi  cient C57BL/6 
kitW-sh/W-sh mice were reconstituted with A2b+/+ or A2b−/− 
BMMCs (referred to as A2b+/+→kitW-sh/W-sh and A2b−/−→
kitW-sh/W-sh mice, respectively). 8 mo after reconstitution, 
PSA experiments were performed as described. As shown in 
Fig. 2 C, A2b−/−→kitW-sh/W-sh mice showed more severe 
anaphylactic response than A2b+/+→kitW-sh/W-sh mice (P < 
0.05), establishing that A2b defi  ciency on mast cells was in-
deed responsible for the enhanced anaphylactic response ob-
served in A2b−/− mice. Collectively, these data derived from 
two mast cell–dependent models of anaphylaxis show that 
the A2b receptor functions as a negative regulator of mast cell 
degranulation in vivo by enhancing the sensitivity of the ani-
mal to the anaphylactic response elicited by antigen.
Enhanced antigen-induced degranulation of A2b−/− BMMCs
To determine the mechanism underlying our in vivo obser-
vations, in vitro experiments were performed with cultured 
Figure 2.  PSA in A2b+/+, A2b−/−, and reconstituted C57BL/6 
kitW-sh/W-sh mice. Mice were intravenously loaded with 20 μg (A, n = 14 
per group; and C, n = 5–6 per group) or 2 μg (B, n = 6 per group) of 
anti-DNP IgE and challenged with DNP-HSA 24 h later. Data represent the 
mean body temperature drop over time after DNP-HSA challenge ± SEM. 
P < 0.05 by repeated measurement analysis of variance (ANOVA; A– C). 
*, P < 0.05; and **, P < 0.01 versus A2b+/+ mice by t test.
Table I.  Mast cell histology in A2b−/− and A2b+/+ mice
Organ Numbers of mast cells (per mm2)
A2b+/+ A2b−/−
Ear pinnae 43.9 ± 1.8 45.8 ± 2.6
Back skin 16 ± 0.8 18.5 ± 2.1
Tongue 10.6 ± 1.2 11.9 ± 2.4
Trachea 4.9 ± 1.1 5.3 ± 0.37
Stomach 6.7 ± 0.6 5.4 ± 0.48120  ENHANCED MAST CELL ACTIVITY IN A2B−/− MICE | Hua et al.
BMMCs. BMMC cultures were established from 14 diff  erent 
A2b−/− mice animals and 14 A2b+/+ littermate controls. The 
growth properties and granule content (determined by total 
hexosaminidase levels after cell lysis with Triton X-100) was 
examined in three of these lines. Morphologically, mast cells 
obtained from A2b−/− mice were indistinguishable from 
those obtained from A2b+/+ animals, and fl  ow cytometric 
analysis of the cultures after 5 wk with antibody directed 
against the FcεRI receptor showed similar numbers of posi-
tive cells, as well as similar levels of receptor expression 
(Fig. S1 A, available at http://www.jem.org/cgi/content/
full/jem.20061372/DC1). To determine the impact of loss 
of the A2b receptor on antigen-induced mast cell degranula-
tion, we measured hexosaminidase release from DNP-HSA 
antigen-stimulated BMMCs that had been cultured over-
night in media containing anti-DNP IgE (Fig. 4 A). At low 
doses of antigen (1 ng/ml), only a modest increase in hexosa-
minidase release above basal levels was observed in BMMCs 
from A2b+/+ mice (from 1.3 ± 0.12 to 6.5 ± 2.1%). In con-
trast, a sevenfold increase in hexosaminidase release above 
baseline was observed in BMMCs from A2b−/− animals 
(from 2.2 ± 0.6 to 20.5 ± 1.2%). Dose-response curves with 
DNP-HSA antigen showed enhanced release in A2b−/− 
BMMCs from 1–100 ng/ml (P = 0.0009).
Enhanced antigen-induced IL-6 release 
from A2b−/− BMMCs
In addition to releasing preformed mediators of anaphylaxis, 
mast cells also synthesize and secrete proinfl  ammatory cytokines 
upon activation. To determine whether the A2b adenosine re-
ceptor could modify proinfl   ammatory cytokine production 
from mast cells, IL-6 levels were measured in the supernatants 
of immunologically activated BMMCs. After incubation with 
antigen for 7 h, BMMCs lacking the A2b receptor released 
higher amounts of IL-6 than those from A2b+/+ animals at sev-
eral diff  erent concentrations of antigen (P < 0.05; Fig. 4 B).
A3 signaling in A2b−/− mast cells
Because we have previously shown that activation of A3 
receptors by exogenous adenosine can potentiate antigen-
induced degranulation of mast cells, we surmised that en-
hanced signaling of endogenous adenosine through the A3 
receptor, either through up-regulated expression or function, 
could explain the increased sensitivity of the A2b−/− mice to 
antigen (6, 19). As shown in Fig. 1 D, A3 expression was 
not up-regulated in the absence of A2b receptors. Because 
a previous report has suggested that the A2b receptor may 
serve as an alternate anchoring protein of ecto–adenosine de-
aminase (ADA), the primary metabolic enzyme of adenosine, 
we postulated that enhanced antigen-induced degranulation 
of BMMCs from A2b−/− mice could be because of less ac-
tivity of ecto-ADA on A2b−/− cells (20). In the absence of 
ecto-ADA, it is possible that endogenous adenosine levels 
could be elevated and potentiate antigen-induced degranuala-
tion through the A3 receptor. To address this possibility, we 
Figure 3.  PCA in A2b+/+ and A2b−/− mice. Mice were intradermally 
injected in the right ears with anti-DNP IgE in 20 μl PBS and in the left 
ears with aliquot vehicle. DNP-HSA/Evans blue solution was intravenously 
administered 24 h later, and Evans blue extravasation into the ears was 
measured. Data represent the mean OD ± SEM (n = 10 mice per group). 
#, P < 0.0001 versus vehicle-treated ears by t test; **, P = 7.36 × 10−6 
versus A2b+/+ ears by t test.
Figure 4.  Antigen-induced degranulation and cytokine production 
from A2b+/+ and A2b−/− mast cells. (A) Degranulation of BMMCs was 
assessed by measuring hexosamindase release from cells incubated with 
anti-DNP IgE after stimulation with increasing doses of DNP-HSA antigen. 
Data are from three different experiments using three different pairs of 
cells and are expressed as the mean percent hexosamindase release ± 
SEM. P < 0.001 by ANOVA. *, P < 0.05; and **, P < 0.005 versus A2b+/+ 
cells by t test. (B) Cytokine production by BMMCs was evaluated by mea-
suring IL-6 release 7 h after antigen stimulation. Cells were incubated 
with anti-DNP IgE and stimulated with 1, 5, or 50 ng/ml DNP-HSA anti-
gen or vehicle, and cytokine levels were determined by ELISA. Data are 
from four different experiments using three different pairs of cells and 
are expressed as the mean IL-6 protein level ± SEM. P < 0.05 by ANOVA. 
*, P < 0.05 versus A2b+/+ cells by t test.JEM VOL. 204, January 22, 2007  121
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treated A2b−/− cells with the potent A3 selective antagonist 
VUF5574 to determine whether antigen-induced degranu-
lation would be attenuated. 50 nM to 100 μM VUF5574 
failed to inhibit antigen-induced degranulation of BMMCs 
from A2b−/− mice (Fig. S2, available at http://www.jem
.org/cgi/content/full/jem.20061372/DC1), suggesting that 
the enhanced antigen-induced degranulation of BMMCs 
observed in A2b−/− mice was not the result of increased sig-
naling through A3 receptors.
Fc𝗆RI expression on A2b−/− mast cells
To determine whether or not enhanced A2b−/− mast cell 
sensitivity to antigen could be caused by up-regulated ex-
pression of FcεRI, we evaluated FcεRI expression on both 
cultured BMMCs and freshly collected peritoneal mast cells. 
Because IgE sensitization can increase FcεRI expression, we 
measured both basal and IgE–up-regulated FcεRI expression 
on these cells. For basal level evaluation, cultured BMMCs or 
freshly collected peritoneal mast cells from both A2b−/− and 
A2b+/+ mice were incubated with fl  uorescently tagged IgE 
antibody for 30 min, and fl  ow cytometry was performed. As 
shown in Fig. S1 (A and B), no diff  erences in basal FcεRI 
expression were detected between A2b−/− and A2b+/+ mast 
cells. For IgE–up-regulated FcεRI expression, both A2b−/− 
and A2b+/+ mice were sensitized by IgE through the tail 
vein, and peritoneal mast cells were collected and analyzed by 
fl  ow cytometry 24 h later. As shown in Fig. S1 B, FcεRI ex-
pression was up-regulated to a similar degree in A2b−/− and 
A2b+/+ mast cells. These data indicate that enhanced antigen 
sensitivity in A2b−/− mice is not caused by up-regulated 
FcεRI expression.
Intracellular cAMP in BMMCs
To determine the mechanism by which disruption of the 
A2b receptor up-regulates mast cell function, we investigated 
the cAMP levels in BMMCs from A2b−/− mice and A2b+/+ 
controls. Activation of A2b receptors has been shown to in-
crease intracellular cAMP levels in diverse cell lines; we thus 
posited that, in the absence of A2b receptors, cAMP levels 
could be reduced (21). As shown in Fig. 5, cAMP levels were 
signifi  cantly lower in A2b−/− BMMCs at the baseline and 
  after antigen stimulation.
Enhanced intracellular calcium infl  ux in A2b−/− BMMCs
Because calcium infl  ux is an essential trigger for exocytosis, 
we measured intracellular cytoplasmic calcium concentration 
([Ca2+]i) in A2b+/+ and A2b−/− BMMCs loaded with Fura-2 
AM, a specifi  c indicator of free calcium. In A2b+/+ cells, 
[Ca2+]i increased after antigen stimulation with 20 ng/ml 
DNP-HSA to fi  ve times the basal level (from 50 to 250 nM), 
whereas in A2b−/− BMMCs, [Ca2+]i increased to nine times 
the basal level (from 50 to 450 nM; Fig. 6 A). To determine 
if the enhanced [Ca2+]i response observed after antigen 
stimulation in A2b−/− cells was caused by up-regulation of 
ER calcium stores or calcium entry from outside of the cells, 
we activated BMMCs with antigen in calcium-free buff  er. 
As shown in Fig. 6 B, antigen initiated a small [Ca2+]i increase 
(two times the basal level), which was not diff  erent between 
A2b+/+ and A2b−/− cells. However, after the addition of ex-
tracellular calcium (fi  nal concentration = 1 mM), calcium 
infl  ux was 1.5 times higher in A2b−/− cells compared with 
A2b+/+ cells. To further verify a role for extracellular cal-
cium infl  ux in the enhanced sensitivity of A2b−/− mast cells, 
we stimulated cells with tharpsigargin (TG), a specifi  c inhibi-
tor of the ER calcium-ATPase. TG treatment in calcium-
free buff  er results in passive release of ER calcium stores, 
independent of upstream signaling events. The TG treatment 
increased [Ca2+]i to a similar extent in A2b−/− and A2b+/+ 
cells suspended in calcium-free buff  er. The reintroduction of 
calcium resulted in a greater infl  ux (1.9 times) of calcium in 
A2b−/− cells compared with A2b+/+ cells (Fig. 6 C). These 
results suggest an enhanced function of store- operated cal-
cium channels (SOCCs) in A2b−/− cells. Next, we examined 
the eff  ects of surrogate Ca2+ ions: Sr2+ and Ba2+. Ca2+ surro-
gates are able to pass through all known store-operated chan-
nels (22) but are not substrates for Ca2+ transporters and do 
not activate most Ca2+-dependent processes to the same ex-
tent as Ca2+. As shown in Fig. 6 D, depletion of calcium 
stores with TG followed by addition of Sr2+ ions at a fi  nal 
concentration of 1 mM resulted in an increase in 340:380 nm 
fl  uorescence ratio. Interestingly, this ratio was only 1.3 times 
higher in A2b−/− compared with A2b+/+ cells. Similar re-
sults were found when Ba2+ was used (not depicted). The 
lower diff  erence in 340:380 nm ratio between A2b−/− and 
Figure 5.  Intracellular cAMP levels in A2b+/+ and A2b−/− mast 
cells. (A) Basal cAMP level in BMMCs from A2b+/+ and A2b−/− mice 
was determined by ELISA. Data are from three separate experiments using 
three sets of cells and are expressed as the mean ± SEM. *, P = 0.03 
versus A2b+/+ cells by t test. (B) cAMP level in both A2b−/− and A2b+/+ 
mast cells at the indicated times after DNP challenge. Data are expressed 
as fold cAMP level relative to A2b+/+ cells, ± SEM.122  ENHANCED MAST CELL ACTIVITY IN A2B−/− MICE | Hua et al.
Figure 6.  Calcium infl  ux in A2b+/+ and A2b−/− mast cells. 
(A–C) Calcium infl  ux in A2b+/+ and A2b−/− BMMCs (anti-DNP IgE preloaded) 
in calcium (A) or calcium-free (B and C) buffer were treated with 20 ng/ml 
DNP-HSA (A and B) or 1 μM TG (C) and, cytosolic-free calcium was mea-
sured as shown. When cells were suspended in calcium-free buffer, extra-
cellular calcium was repleted to fi  nal a concentration of 1 mM after 
DNP-HSA or TG challenge. (D) Increased Ca2+ surrogate Sr2+ infl  ux in 
A2b−/− cells. A2b+/+ or A2b−/− BMMCs in calcium-free buffer were chal-
lenged with 1 μM TG, and Sr2+ was added to a fi  nal concentration of 1 mM. 
Sr2+ infl  ux was recorded as shown. (E) Mean fold increase of intra-
cellular Ca2+ or Sr2+ concentrations, ± SEM, in A2b−/− cells compared 
with A2b+/+ cells after FcεRI-mediated activation. (F and G) Increased 
Ca2+ surrogate Sr2+ infl  ux in A2b−/− cells. A2b−/− and A2b+/+ BMMCs 
(anti-DNP IgE preloaded) in calcium-free buffer were triggered by DNP-
HSA (F) or TG (G), and bivalent cations were recovered by successive addi-
tion of 1 mM Sr2+ and 1 mM Ca2+ as shown. Representative results from 
at least three independent experiments and two sets of cells are shown. 
Ag, antigen.JEM VOL. 204, January 22, 2007  123
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A2b+/+ cells in the presence of Sr2+ or Ba2+ compared with 
Ca2+ suggested that the A2b receptor may infl  uence both 
nonselective cation channels (NSCCs) and SOCCs. This was 
further supported by the observations that mixtures of Ca2+/
Sr2+ ions further increased the 340:380 nm fl  uorescence ratio 
compared with Sr2+ or Ba2+ alone. Diff  erences in response 
between A2b−/− and A2b+/+ mast cells increased from 1.3 in 
the presence of Sr2+ only to 1.7 in the presence of Ca2+/Sr2+ 
mixtures (Fig. 6 F). Similar results were found with TG (Fig. 
6 G). Interestingly, extracellular calcium infl  ux in A2b−/− 
and A2b+/+ mast cells was blocked when 10 μM La3+ was 
added in the presence of Ca2+, Sr2+, or Ca2+/Sr2+ ions (not 
depicted). Collectively, these fi  ndings show that the A2b re-
ceptor regulates store-operated calcium infl  ux into the mast 
cell and suggest that these eff  ects are not isolated to a specifi  c 
calcium channel.
Effects of dibutyryl cAMP (dbcAMP) on degranulation 
and antigen-induced calcium infl  ux in A2b−/− 
and A2b+/+ mast cells
To investigate whether the observed alteration in cAMP 
could be mechanistically related to the changes in mast cell 
Figure 7.  Inhibitory effect of cAMP analogue on hexosaminidase 
release and SOCCs on mast cells. (A) Inhibitory effect of cAMP ana-
logue on antigen-induced degranulation of both A2b+/+ and A2b−/− mast 
cells. Anti-DNP IgE preloaded A2b−/− and A2b+/+ BMMCs were treated 
with 3 mM dbcAMP for 30min before the challenge with 10 ng/ml DNP, 
and the effect of dbcAMP on antigen-induced degranulation of A2b−/− 
and A2b+/+ BMMCs was measures as shown. Data represent mean hex-
osaminidase release, ± SEM, from four separated experiments using three 
different sets of cells. *, P < 0.05 by t test. (B–E) Inhibitory effect of cAMP 
analogue on antigen- (B–D) or TG-induced (E) calcium infl  ux in both 
A2b+/+ and A2b−/− mast cells. Both A2b−/− and A2b+/+ BMMCs in 
  calcium (B and C) or calcium-free (D and E) buffer were treated with 
dbcAMP buffer were treated with dbcAMP and DNP-HSA (B–D), or 
TG-induced (E) calcium infl  ux was recorded. When cells were suspended 
in calcium-free buffer (D and E), extracellular calcium was restored 10 min 
after the addition of antigen (D) or TG (E). Representative results from 
at least three independent experiments and two sets of cells are shown. 
(F) Anti-DNP IgE preloaded A2b−/− and A2b+/+ BMMCs were treated with 
50 nM of PKA inhibitor KT5720 for 30 min, and the dbcAMP effect on 
antigen-induced calcium infl  ux was reevaluated as shown. Data represent 
mean [Ca2+]i , ± SEM, from three independent experiments and two sets 
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degranulaion, hexosaminidase release in BMMCs was mea-
sured after treatment with dbcAMP. As shown in Fig. 7 A, 
dbcAMP treatment inhibited degranulation in A2b+/+ and 
A2b−/− BMMCs. The mechanism behind these inhibitory 
eff  ects of cAMP on mast cell degranulation are poorly under-
stood (23–25). In our experiments, we observed that higher 
[cAMP]i in A2b+/+ BMMCs relative to A2b−/− cells was as-
sociated with decreased extracellular calcium infl  ux into the 
cell. To determine whether these alterations in cAMP and 
calcium might be related, we treated cells with the dbcAMP 
and observed its eff  ects on calcium signaling. As shown in 
Fig. 7 B, treatment of A2b+/+ BMMCs with the cAMP ana-
logue reduced total calcium infl  ux into the cell. Pretreatment 
of A2b−/− BMMCs with dbcAMP lowered the magnitude of 
calcium infl  ux to that observed in A2b+/+ cells (i.e., reduced 
the diff   erence of antigen-driven calcium infl  ux  between 
A2b−/− and A2b+/+ cells; Fig. 7 C). When cells were sus-
pended in calcium-free buff  er, the release of internal calcium 
stores was minimally or not aff  ected by dbcAMP treatment, 
but infl  ux of extracellular calcium was reduced after store de-
pletion by antigen or TG (Fig. 7, D and E). Collectively, 
these results suggest that cAMP levels within the mast cell can 
infl  uence antigen-induced mast cell degranulation by altering 
calcium infl  ux through SOCCs on the cell membrane. To 
further elucidate the mechanism by which cAMP modifi  es 
SOCCs, we pretreated BMMCs with the protein kinase A 
(PKA) inhibitor KT5720 before addition of dbcAMP. 
As shown in Fig. 7 F, 50 nM KT5720 inhibited dbcAMP-
mediated attenuations of calcium infl  ux, suggesting that the 
eff  ect of cAMP on SOCC channel activity is indirect via a 
PKA-dependent mechanism.
D  I  S  C  U  S  S  I  O  N 
Mast cell activation mediated by FcεRI is a critical event in 
the allergic infl  ammatory response. The potency of adenosine 
as a modulator of mast cell function is well recognized, 
and adenosine receptors are of considerable interest as thera-
peutic targets for asthma and allergy (9, 26). Although in 
  vitro studies have suggested roles for each adenosine recep-
tor on the mast cell, the biological function of these receptors 
on mast cells in vivo, particularly A2b receptors, is largely un-
known (5, 19, 21). In this study we show, using mice lacking 
the A2b receptor, a surprising nonredundant role for this 
  adenosine receptor as a negative regulator of mast cell function. 
Mice lacking the A2b receptor demonstrated heightened sus-
ceptibility to antigen-induced anaphylaxis. In vitro studies 
with cultured mast cells from these same animals showed 
greater calcium infl  ux through SOCCs after activation with 
antigen, which correlated with enhanced degranulation and 
cytokine production. cAMP levels were markedly lower in 
mast cells from A2b−/− mice, suggesting that A2b-Gs signal-
ing may be of fundamental importance in the constitutive 
control of cyclic nucleotide levels within mast cells, and by 
extension a critical regulator of cellular activation.
Our results are in contrast to fi  ndings with HMC-1 cells 
in which the A2b receptor has been shown to subserve a 
proinfl   ammatory role. Feoktistov et al. reported that the 
nonselective adenosine analogue NECA could induce IL-8 
released from HMC-1 cells. Lack of such an eff  ect by the 
A2a-selective agonist CGS21680, failure of an A3 receptor 
antagonist to abolish the response, and blockade of NECA-
induced IL-8 release by either 300 μM enprofylline or 3-iso-
butyl-8-pyrrolidinoxanthine suggested that A2b receptors 
were mediating this action of adenosine in this cell line 
(4, 12, 13). A2b receptor activation on HMC-1 cells results 
in mobilization of intracellular calcium through a Gq-coupled 
signaling pathway, potentially explaining the capacity of this 
receptor to transmit a proinfl  ammatory signal in this cell line (4). 
Similar fi   ndings of A2b-linked calcium mobilization have 
been found in canine mastocytoma cells, with NECA-
  induced degranulation attributed to activation of the A2b 
  receptor (10). To our knowledge, A2b-mediated calcium 
mobilization in mast cells has only been observed under con-
ditions of forced expression in transfection experiments and 
in some poorly diff   erentiated mast cell lines, which have 
many acquired phenotypic diff  erences from normal, nonma-
lignant mast cells, most notably their lack of FcεRI and their 
diff  erent profi  les of ion channels (15–17, 27, 28). Our previ-
ous data have shown that either A3 receptor deletion or A3 
selective antagonism could totally abolish adenosine-induced 
calcium infl  ux in both BMMCs (unpublished data) and pri-
mary lung mast cells, suggesting that A2b-Gq coupling may 
be a unique feature of these manipulated and malignant mast 
cell lines (7).
Although our study is the fi  rst to use a genetic approach 
to characterize the function of A2b on mast cells, many stud-
ies support an antiinfl   ammatory role for this receptor on 
other immune cells. First, the A2b receptor has been shown 
to couple to Gs proteins in all cells types examined (21). Ele-
vations in cAMP, as the result of adenylate cyclase activation, 
have been repeatedly shown to inhibit the function of 
  immune cells, including mast cells (23–25, 29). Second, in 
human T lymphocytes, A2b receptors are up-regulated after 
lymphocyte activation by phytohemagglutinin or anti–T cell 
receptor–CD3 complex antibodies and are functional as IL-2 
production is reduced by NECA but not by the A2a-selec-
tive agonist CGS21680 (30). Finally, both pharmacological 
and genetic studies have attributed adenosine-mediated inhi-
bition of macrophage function to A2b. In A2a receptor–defi  -
cient mice, A2b receptors have been shown to inhibit TNF 
release induced by thioglycollate, and up-regulated A2b ex-
pression correlates with increases in cAMP production in 
mouse macrophages treated with adenosine receptor agonists; 
IFN-γ–induced proinfl  ammatory cytokine release by macro-
phages is inhibited by activation of A2b receptor; and 
  adenosine can increase antiinfl  ammatory cytokine IL-10 release 
by macrophage (14, 31, 32). Recently, genetic studies have 
also shown an inhibitory role for A2b receptors on macro-
phages. Yang et al. found up-regulated release of multiple 
proinfl  ammatory cytokines by mouse macrophages lacking 
the A2b receptor under both basal conditions and after acti-
vation by LPS (33). Collectively, our fi  ndings and those JEM VOL. 204, January 22, 2007  125
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  described in this section support an antiinfl  ammatory func-
tion of A2b receptors on immune cells.
A surprising fi  nding from our studies was the marked 
  reduction in basal cAMP levels in BMMCs isolated from 
A2b−/− animals. There are at least two possible explanations 
for this fi  nding. First, autocrine and paracrine adenosine pro-
duced in the BMMC cultures could activate A2b receptors 
on the mast cell surface and contribute to the maintenance of 
cyclic nucleotide levels within the cell. In the absence of 
A2b, this signal would be lost and cAMP levels might fall. 
However, because of the low affi   nity of this receptor for 
  adenosine, it is unlikely that endogenous adenosine at physiolog-
ical levels would be capable of activating the A2b receptor. 
A second and more plausible explanation for our fi  ndings is 
that the A2b receptor may have intrinsic, spontaneous activity. 
The capacity of G protein–coupled receptors (GPCRs) to 
achieve a constitutively active conformation in the absence of 
ligand is well recognized; however, the level of such activity 
diff  ers among GPCRs (34, 35). For example, even the same 
GPCR can have diff  erent levels of constitutive activity inde-
pendent of its intrinsic molecular properties, depending on 
the cell types on which it is expressed (35). Our data showing 
enhanced mast cell function in A2b−/− mice, but normal 
basal hemodynamics, suggest a constitutive role for A2b on 
mast cells but not vascular smooth muscle cells (VSMCs). 
Indeed, it has recently been shown that VSMCs lacking A2b 
receptors have similar basal levels of cAMP compared with 
A2b+/+ VSMCs (33). The concept of constitutive activation 
of A2b receptors on mast cells raises important questions 
about the use of A2b antagonists in asthmatics. A2b antago-
nists with inverse agonist activity could result in the lowering 
of cAMP levels within the mast cell, potentially enhancing 
antigen-induced degranulation and proinfl  ammatory cyto-
kine production.
Antigen-induced mast cell degranulation is a well-coor-
dinated event requiring several essential steps, including the 
cross-linking of IgE by antigen, activation of tyrosine kinases 
by FcεRI, and, fi  nally, fusion of mast cell granules with the 
cell membrane (36, 37). Critical to this fusion event is the in-
fl  ux of extracellular calcium through SOCCs, activated when 
calcium stores are depleted by the interaction of inositol tris-
phosphate with the endoplasmic reticulum (2, 38). In our 
studies, enhanced degranulation of A2b−/− BMMCs was as-
sociated with enhanced extracellular calcium infl  ux. To in-
vestigate whether reduced cAMP levels could be linked to 
enhanced calcium infl  ux, we examined calcium signaling af-
ter pharmacological manipulation of cAMP within BMMCs. 
In our studies we found an inhibitory eff  ect of the cAMP an-
alogue dbcAMP on the antigen-induced cytosolic-free cal-
cium increase in BMMCs, which was achieved by reducing 
the calcium infl  ux from the extracellular matrix rather than 
by inhibiting calcium release from the ER. This inhibitory 
eff  ect of dbcAMP on extracellular calcium infl  ux was verifi  ed 
when we observed similar results in BMMCs treated with the 
ER calcium-depleting agent TG. These fi  ndings not only 
imply that the enhanced antigen-driven calcium infl  ux  in 
A2b−/− BMMCs may be attributable to the lower cAMP 
level, they also provide a reasonable explanation for the 
widely accepted observation that increased cAMP levels are 
associated with impaired antigen-driven mast cell activity.
An inhibitory eff  ect of cAMP on store-operated calcium 
infl  ux has recently been shown in other cell lines. Ay et al. 
found that both cAMP analogues and forskolin, through the 
downstream kinase system, were able to inhibit calcium in-
fl  ux through La3+/Ni2+-sensitive SOCCs, which corres-
ponded well with cAMP-induced airway dilation (39). The 
profi  le of calcium channels on mast cells, which is reported to 
include the NSCCs and SOCCs but varies among mast cell 
lines, has not yet been identifi  ed (27, 40). Both NSCCs and 
SOCCs on mast cells belong to the transient receptor poten-
tial family of channels, which is gated by the signal of ER 
calcium depletion and dependent on transmembrane poten-
tial diff  erence (41). The mechanism by which cAMP infl  u-
ences SOCCs is unknown. One possibility is that cAMP 
infl  uences SOCC activity indirectly by changing membrane 
potential through other ion channels. For example, in rat 
peritoneal mast cells, cAMP can elicit a delayed chloride ion 
infl   ux, which results in hypopolarization of the mast cell 
membrane (41). However, recent experiments have shown 
that mast cells can also secrete chloride ion through the 
cAMP-gated cystic fi  brosis transmembrane conductance reg-
ulator (42). The cAMP-driven chloride ion trans-membrane 
transit, which subsequently alters the transmembrane poten-
tial, is believed to considerably infl  uence the magnitude of 
calcium infl  ux into the cell. Potassium and sodium channels 
have also been identifi  ed on diff  erent mast cell lines and are 
believed to contribute to polarization of the cell membrane 
(27, 40). The exact roles of these ion channels on mast cells, 
and whether second messengers can modify their properties, 
are still areas of active investigation.
It has long been recognized that elevations of intracellular 
cAMP can inhibit mast cell function. However, the mecha-
nism by which cyclic nucleotides regulate the function of 
mast cells is not well understood. Our data suggest that cAMP 
levels within the mast cell infl  uence the activity of cell mem-
brane–associated calcium channels, the fi  nal common path-
ways for cellular activation. Moreover, our studies have 
iden  tifi  ed a nonredundant role for the Gs-coupled A2b 
  adenosine receptor as a critical regulator of cAMP levels within 
mouse mast cells, with functional consequences of enhanced 
mast cell activation in its absence. If similar control of human 
mast cells is also attributable to the constitutive expression of 
A2b receptors, then these fi  ndings may have important im-
plications as adenosine receptor ligands are developed and 
tested for the treatment of asthma and allergy.
MATERIALS AND METHODS
Animal welfare. The use of experimental animals was in accordance with 
the Institutional Animal Care and Use Committee guidelines of the Univer-
sity of North Carolina at Chapel Hill.
Generation of A2b-defi  cient mice. A 15-kb genomic region of the A2b 
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ES cells and subsequently subcloned into pBluescript II KS(+). The plasmid 
pJNS2 was used to construct the A2b targeting vector by replacing a portion 
of the endogenous gene with a neomycin-resistant gene, resulting in the dis-
ruption of the A2b gene after homologous recombination. The targeted 
plasmid was linearized at the Not I site and introduced into the E14TG2a ES 
cell line by electroporation, and clones that were resistant to both G418 and 
gancyclovir were identifi  ed by standard methods, as previously described 
(43). Isolated clones were screened for the desired recombination event by 
Southern blot analysis. The positively targeted cell lines were microinjected 
into 3.5-d-old C57BL/6 blastocysts to generate chimeras that were capable 
of transmitting the mutant allele to their off  spring. Male chimeras were 
mated to C57BL/6 females to generate heterozygous animals for the mutant 
allele. These heterozygous mice were subsequently backcrossed to C57BL/6 
for six generations. After six generations of backcrosses, heterozygous mice 
were intercrossed to generate homozygous mice for the A2b mutation 
(A2b−/−) and A2b+/+ littermate controls (A2b+/+).
Genotyping. Genomic DNA was isolated from ES cell clones and from tail 
biopsies of neonates by high salt precipitation and analyzed by genomic 
Southern blotting as previously described (19).
Northern blot analysis. Northern blot analysis of A2b mRNA in the 
brains and kidneys from A2b−/− and A2b+/+ mice was performed as previ-
ously described (19).
Real-time RT-PCR analysis. Real-time RT-PCR for evaluation of ex-
pression of adenosine receptor subtypes on BMMCs from A2b−/− and 
A2b+/+ mice was performed using a sequence detector (model 7700; Ap-
plied Biosystems) as previously described (7).
Blood pressure measurements. Systolic blood pressure and heart rate 
measurements were made in conscious mice using a noninvasive computer-
ized tail-cuff   system as previously described (44). For each mouse, eight 
measurements were performed in eight diff  erent channels on the tail-cuff   
system on a daily basis during eight consecutive days, and the mean of the 
eight measurements was taken as the data point of the mouse. Measurements 
were performed during a fi  xed time period each day.
PSA. PSA was performed as previously described (6). Mice were injected 
intravenously with 20 or 2 μg mouse anti-DNP IgE mAb (Sigma-Aldrich) 
via the tail vein. 24 h after IgE loading, 1 mg DNP-HSA was injected 
  intravenously. Core body temperatures were recorded over time. Negative 
controls received either IgE + Evans blue or DNP-HSA + Evans blue. 
  Investigators were blinded to genotype during all experiments.
PCA. PCA was performed as previously described (6). Animals were lightly 
anesthetized, and the right ears were injected intradermally with 1 or 100 ng 
anti-DNP IgE mAb in 20 μl PBS. The left ears were injected with 20 μl 
PBS. 24 h later, animals were injected intravenously with 100 μl of 1% 
  Evan’s blue dye containing 100 μg DNP-HSA. Animals were killed 90 min 
after intravenous injection, and ear biopsies were incubated in 1 ml formamide 
at 54°C for 48 h. Quantitative analysis of formamide extracts was determined by 
measuring the absorbance of Evans blue at 610 nm with a spectrophoto  meter. 
Investigators were blinded to genotype during all experiments.
BMMC culture, hexosaminidase release, and IL-6 measurement. 
BMMCs were isolated from 8–16-wk-old mice and grown in RPMI 1640 
medium supplemented with 10% FCS, 20 ng/ml mouse IL-3, and 20 ng/ml 
stem cell factor, as previously described (45). Cell purity was determined by 
toluidine blue staining and fl  ow cytometric analysis for FcεRI expression. 
Mast cell degranulation was determined by β-hexosaminidase activity assay 
as previously described (19). Antagonist, or cAMP analogue, if used before 
antigen introduction, was added as indicated in the fi  gures. IL-6 measure-
ment was performed by ELISA (Assay Design). Samples were prepared as 
previously described (46).
Mast cell histology. Mast cell histology was performed as previously 
  described (6, 47). In brief, organs from three sets of A2b−/− and A2b+/+ litter-
mates were harvested and fi  xed in 10% formalin. After paraffi   n embedding, 
5-μm sections were cut and stained with toluidine blue. Mast cells were rec-
ognized by positively staining cells and counted in a blinded fashion.
Reconstitution of mast cells. Reconstitution of A2b−/− and A2b+/+ mast 
cells was performed as previously described (47). In brief, BMMCs from 
A2b−/− and A2b+/+ littermate controls were cultured for 5 wk. Mice defi  -
cient in mast cells (kitW-sh/W-sh) were reconstituted with six million of either 
A2b−/− or A2b+/+ BMMCs by tail-vein injection. Reconstituted mice were 
housed in pathogen-free circumstance with 12 h of day/night shifts for 8 mo. 
Confi  rmation of mast cell reconstitution in these recipients was histologically 
confi  rmed by toluidine blue staining of tissues from several diff  erent organs.
Flow cytometric analysis. Flow cytometric analysis of FcεRI expression 
on BMMCs and freshly collected peritoneal mast cells from both A2b−/− and 
A2b+/+ mice was performed as described previously (48).
Intracellular cAMP assay in BMMCs. Intracellular cAMP was measured 
as previously described with some modifi  cation (46). In brief, cells were 
washed with Tyrode’s solution (137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 
1.8 mM CaCl2, 0.2 mM NaH2PO4, 12 mM NaHCO3, and 5.5 mM 
d-Glucose) twice. Two million cells were lysed, and cAMP was measured using 
the Direct cAMP kit according to the manufacture’s protocol (Assay De-
signs). For measurement of cAMP levels after DNP challenge, BMMCs 
were loaded with IgE mAb at 100 ng/ml/1 × 106 cells overnight. Cells were 
washed twice with Tyrode’s buff  er and resuspended at 2 × 107 cells/ml. 
One million cells were used and treated with DNP at 3 ng/ml for 20 s or 
3 min. cAMP levels were determined as described in this section.
Intracellular calcium measurement. [Ca2+]i was determined by a micro-
plate reader (FLUOstar OPTIMA; BMG Labtechnologies), as previously de-
scribed (45). In brief, BMMCs were loaded with mouse anti-DNP IgE 
overnight (100 ng/1 × 106 cells/ml). Cells were washed with calcium buff  er 
(137 mM NaCl, 2.7 mM KCl, 0.2 mM NaH2PO4, 5.5 mM glucose, 1 mM 
CaCl2, 1 mM MgCl2, 12 mM NaHCO3, 10 mM Hepes, and 0.1% BSA) twice 
and loaded with Fura-2 AM (1 μg/2 × 106 cells/ml) at 37°C for 40 min. After 
loading, cells were washed twice with calcium buff  er, and 2 × 105 cells were 
transferred to black-wall 96-well microplates (Becton Dickinson). After basal 
[Ca2+]i was determined, cells were challenged with DNP-HSA. In some ex-
periments, cells were washed in calcium-free buff   er (containing 0.2 mM 
EDTA), and cells were activated with DNP-HSA or TG after 2 min at 37°C. 
The extracellular Ca2+ was restored to 1 mM after an additional 5 min. For 
evaluation of Ca2+-specifi  c store-operated channel responses, 1 mM Sr2+ or 
1 mM Ba2+ ions were used instead of Ca2+. Real-time fl  uorescence signal was 
measured with excitement wavelengths 340 and 380 nm and with a constant 
emission at 510 nm. Intracellular calcium level was calculated as previously de-
scribed (49). For Sr2+ and Ba2+ ions, the ratio of fl  uorescence in 340 and 380 
nm was used instead of concentration. For data reported as fold increase 
  between genotypes, calculations were done using the highest point in the curve.
cAMP analogue eff  ect on SOCCs. cAMP analogue eff  ect on SOCCs 
was also performed on the FLUOstar OPTIMA microplate reader. In brief, 
after IgE and Fura-2 AM loading, 2 × 105 cells in either calcium or calcium-
free buff  er were transferred to black-wall 96-well microplates and treated 
with 3 mM dbcAMP in distilled/deionized water. Controls were set up by 
adding aliquot vehicle only. 3 min later, cells was challenged with either an-
tigen or TG and cytosolic-free calcium was monitored. Extracellular calcium 
was restored 10 min after the addition of stimulant when cells were in 
  calcium-free buff  er.
For preinhibition of PKA before dbcAMP addition, 50 nM of PKA 
  inhibitor (KT5720; EMD Bioscience) was introduced into both A2b−/− 
and A2b+/+ mast cells suspended in calcium buff   er 30 min before 
dbcAMP treatment.JEM VOL. 204, January 22, 2007  127
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Online supplemental material. Fig. S1 A shows the expression of FcεRI 
receptors on cultured BMMCs from A2b−/− and A2b+/+ mice. Fig. S1 B 
shows the expression of FcεRI receptors on freshly collected peritoneal 
mast cells from A2b−/− and A2b+/+ mice. Fig. S2 shows the eff  ect of A3-
selective antagonist VUF5574 on antigen-induced activation of A2b−/−
mast cells. Supplemental materials and methods describes mouse   peritoneal 
lavage. Online supplemental material is available at http:www.jem.org/
cgi/content/full/jem.20061372/DC1.
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